This SWAV stock forecast article was written by Anastasia Makuyev – Quantitative Analyst at I Know First.

Summary:

• Shockwave Medical is innovating cardiovascular treatment with its Intravascular Lithotripsy (IVL) technology, which uses sonic pressure waves for minimally invasive procedures.
• Recent financials showcase robust growth, with a YoY increase of 72% in Q1 2023 revenues and expectations of future growth, making it an appealing target for potential acquisitions.
• Rumors of a takeover from giants like Johnson & Johnson and Medtronic have surfaced, yet irrespective of such speculations, Shockwave’s strong financial performance and differentiated technology make it a compelling investment.

An Overview of Shockwave Medical

Established as a key player in the medical device arena, Shockwave Medical specializes in the treatment of calcified cardiovascular disease. The company’s unique approach involves IVL technology that utilizes sonic pressure waves to safely break down calcified plaques in the arteries. This novel treatment has the potential to become a game-changer in addressing conditions like Peripheral Artery Disease (PAD) and Coronary Artery Disease (CAD).

Shockwave’s dedication is evident in their investor presentation. Their mission? “To transform the treatment of calcified cardiovascular disease” and “establish a new standard of care through intravascular lithotripsy (IVL).” With a market opportunity exceeding $8.5 billion, Shockwave is geared up to simplify procedures, optimize outcomes, and offer clinically validated solutions.

The Science Behind Shockwave’s Solution

Cardiovascular diseases like atherosclerosis, characterized by the narrowing of arteries due to plaque buildup, pose significant challenges to treatment. A major obstacle arises when calcium accumulates within the plaque, making the arteries resistant to expansion. This results in increased complications and potential damage to the vessel.

Traditional methods to treat these calcifications include high-pressure balloons and atherectomy. However, these methods have limitations. High-pressure balloons can lead to significant complications such as dissections and perforations, especially near the calcified areas. Atherectomy, while effective, involves a steep learning curve and has its own set of complications, including thermal injury and potential blockage of downstream arteries.

Enter Shockwave’s IVL technology. Inspired by lithotripsy’s success in treating kidney stones, the IVL method cracks calcium without harming the surrounding soft tissue. The catheter-based solution offers a localized treatment that dilates vessels under low pressure, effectively addressing both superficial and deep arterial calcium.

M&A Buzz and Financial Performance

Recent speculations hint at potential takeover interest in Shockwave Medical from industry giants such as Johnson & Johnson and Medtronic. These rumors have fueled interest in the company, especially after the reported unsuccessful talks with Boston Scientific. Yet, as Seeking Alpha’s analyst Stephen Ayers opines, even without a takeover, Shockwave remains a sound investment.

In Q1 2023, Shockwave reported an impressive revenue of $161.1M, marking a 72% YoY increase primarily attributed to increased catheter sales. With an 87% gross margin and a net income of $39.1M, the company’s financial health is evident. These strong financials are complemented by a promising revenue growth forecast and a substantial cash position.

The Path Forward

Shockwave is not resting on its laurels. The company plans to roll out new products, such as the next-generation coronary product C2+. Their ambition? To release two new products annually until 2026. They also have an optimistic outlook on their recent acquisition, Neovasc, and its Reducer System.

Every investment harbors risks. While Shockwave’s forward P/E ratio suggests potential overvaluation, it’s essential to balance this against their impressive sales growth and product pipeline. The looming shadow of potential mergers and acquisitions, while promising, also introduces volatility.

In the fast-paced world of medical technology, where change is the only constant, Shockwave Medical offers a blend of innovation and robust financial health. For investors with an appetite for growth and a tolerance for risk, it appears to be a sound choice in the cardiovascular sector.

Analysis & Potential Risks

While Shockwave’s prospects seem promising, potential investors should be mindful of inherent risks in the healthcare sector. The high valuation of the stock, as indicated by its forward P/E ratio, suggests that the stock may be more suitable for growth-focused investors comfortable with a higher risk level. Furthermore, the competitive landscape of the medical device industry means that technological advancements from competitors could threaten Shockwave’s market share. Regulatory hurdles and the outcomes of clinical trials will also play a significant role in the company’s future trajectory.

What Are Other Analysts Saying?

According to Yahoo! Finance, it is evident that other analysts are leaning towards a “buy” outlook on SWAV.

Conclusion

Shockwave Medical stands out as a beacon of innovation in the medical device industry. Its focus on addressing the challenges of calcified cardiovascular diseases through its IVL technology positions it as a potential market leader in the coming years.

Considering these factors and the potential for continued market penetration, my price target for SWAV stands at $245 in the next year. For the astute investor, Shockwave presents a blend of risk and reward, much like Tesla did in its nascent stages. Just as Tesla wasn’t merely about electric cars but a broader vision of sustainable energy, Shockwave isn’t just about a single technology; it’s about a more holistic approach to cardiovascular health. The journey ahead is teeming with potential, and for those willing to navigate its intricacies, the destination seems promising.

Worth noting is that the AI-driven stock selection by I Know First indicates a strong bullish signal for SWAV stock on the one-year market trend predictions, aligning with my perspective. The light green for short-term forecasts suggests a mildly bullish stance, while the darker green represents a strong bullish signal for the one-year forecast.

Past Success With SWAV Forecast

I Know First has been bullish on the SWAV stock forecast in the past. On August 3^rd, 2022 the I Know First algorithm issued a forecast for SWAV stock price and recommended SWAV as one of the best 52 Week High stocks to buy. The AI-driven SWAV stock prediction was successful on a 3-month time horizon resulting in more than 26.77%.

To subscribe today click here.

Please note-for trading decisions use the most recent forecast.